US Patent

US12569543 — Semaglutide in cardiovascular conditions

Method of Use · Assigned to Novo Nordisk AS · Expires 2037-04-28 · 11y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of semaglutide, a GLP-1 receptor agonist, in medicine.

USPTO Abstract

The present invention relates to the GLP-1 receptor agonist semaglutide for use in medicine.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4446 — Ozempic
U-4443 — Ozempic
U-4443 — Ozempic
U-4443 — Ozempic
U-4443 — Ozempic
U-4443 — Ozempic
U-4443 — Ozempic
U-4446 — Ozempic
U-4446 — Ozempic

Patent Metadata

Patent number
US12569543
Jurisdiction
US
Classification
Method of Use
Expires
2037-04-28
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.